This document discusses strategies for improving global cardiovascular health, including political and economic factors influencing non-communicable diseases, the WHO's "25 by 25" goals, and polypills. It outlines WHO's proposed targets to reduce premature mortality from non-communicable diseases by 25% by 2025. It also discusses research on polypills, including a study in India that found a polypill reduced cardiovascular risk factors but not to the extent originally predicted, and had 16% of patients permanently stop medications after 12 weeks. Overall the document analyzes political, economic and scientific factors impacting efforts to address non-communicable diseases globally.
This document provides a summary of a company's future process model for a high-level business function. It includes an event catalog, process listings and descriptions, process relationships, a function hierarchy, process step catalogs, process flow diagrams, and open/closed issues. The goal is to outline the key processes and how they will interact to carry out the business function.
This document provides an overview of ShortCourses and PhotoCourse, which are publishers of digital photography books and textbooks. They publish books on specific cameras and digital photography topics. The books are used in classrooms and training programs. Special pricing is available for classroom use. The document also provides contact information for the publisher and copyright details.
A classic "How to" Wet Shave from 1905. An entertaining read for a wet shaving enthusiast. Still contains relevant information from a barber's perspective. Enjoy! Visit: http://howtogrowamoustache.com
La pandemia de COVID-19 ha tenido un impacto significativo en la economía mundial. Muchos países experimentaron fuertes caídas en el PIB y aumentos en el desempleo debido a los cierres generalizados y las restricciones a los viajes. Aunque las vacunas han permitido la reapertura de muchas economías, los efectos a largo plazo de la pandemia en sectores como el turismo y los viajes aún no están claros. Se espera que la recuperación económica mundial sea desigual y dependa de factores como el control
This document provides a summary of a company's future process model for a high-level business function. It includes an event catalog, process listings and descriptions, process relationships, a function hierarchy, process step catalogs, process flow diagrams, and open/closed issues. The goal is to outline the key processes and how they will interact to carry out the business function.
This document provides an overview of ShortCourses and PhotoCourse, which are publishers of digital photography books and textbooks. They publish books on specific cameras and digital photography topics. The books are used in classrooms and training programs. Special pricing is available for classroom use. The document also provides contact information for the publisher and copyright details.
A classic "How to" Wet Shave from 1905. An entertaining read for a wet shaving enthusiast. Still contains relevant information from a barber's perspective. Enjoy! Visit: http://howtogrowamoustache.com
La pandemia de COVID-19 ha tenido un impacto significativo en la economía mundial. Muchos países experimentaron fuertes caídas en el PIB y aumentos en el desempleo debido a los cierres generalizados y las restricciones a los viajes. Aunque las vacunas han permitido la reapertura de muchas economías, los efectos a largo plazo de la pandemia en sectores como el turismo y los viajes aún no están claros. Se espera que la recuperación económica mundial sea desigual y dependa de factores como el control
The Power of Vaccines: ‘getting to zero’ for HIV and TB was an event hosted by the TB/HIV and Prevention Working Groups of the UK Consortium on AIDS and International Development. The meeting was sponsored by Pamela Nash MP and held on Friday, 18th May 2012, in Portcullis House, Westminster. Read more at http://storify.com/PamojaUK/the-power-of-vaccines
http://www.pamoja.uk.com
This document discusses the past, present and future of global health engagement by academic institutions. It provides a brief history of global health, from tropical medicine to international health to global health. It discusses definitions of global health and international health. It also outlines the growing interest in global health engagement, including changing US demographics, educational benefits for students, and a commitment to social justice. Key players in global health like the WHO, World Bank, and Gates Foundation are also summarized.
This document discusses lessons that can be learned from international healthcare systems to develop a sustainable healthcare system. It provides 3 key lessons:
1. Prioritize health in policymaking by demonstrating how health impacts productivity, education, employment and economic growth.
2. Increase investment in healthcare through dedicated funding and by legislating specific access entitlements.
3. Engage patients by making services patient-centered, ensuring quality communication of information, and driving continuous quality improvement.
1. Medical technology provides substantial benefits to patients' quality of life, disability levels, and mortality rates compared to traditional treatments like drugs alone.
2. While medical technology increases direct health care costs, it also provides significant economic and productivity benefits to society by reducing time lost from work and increasing overall welfare.
3. Studies show that many medical technologies reduce overall lifetime health care costs and societal costs compared to traditional treatments due to better health outcomes and shorter hospital stays.
Dr. Michael S. Perry - Afternoon Keynote Presentationmarsinnovation
Michael Perry gave a presentation at the MaRS Innovation Summit in Toronto, Canada on October 28, 2010. He discussed trends in pharmaceutical R&D including rising costs of drug development and declining productivity. He noted significant unmet medical needs in areas like oncology, cardiovascular disease, and diabetes. Perry also talked about how venture capital like Bay City Capital is fueling innovation by translating academic research into potential drugs and funding their development through commercialization. However, industry faces challenges like large patent cliffs and risk aversion. Perry proposed strategies like the Pharma Innovation Fund to help bridge gaps in translating discoveries into treatments.
This document discusses the role of evidence and global partnerships in addressing major global health issues and achieving the UN Millennium Development Goals. It outlines how organizations like the World Health Organization, World Bank, and Lancet work together through initiatives like Countdown 2015 and strategic partnerships to generate scientific evidence, advocate for policies, and monitor programs aimed at reducing child and maternal mortality globally. The document also previews upcoming reports from the Lancet on various global health topics like mental health, HIV prevention, and non-communicable diseases.
This document summarizes the work of Dr. Kevin Patrick and the Center for Wireless and Population Health Systems at UC San Diego. The center conducts research using wireless technologies to measure health behaviors and exposures in various populations. This includes projects funded by NIH on personal activity and location tracking, comparative effectiveness research, and text message interventions for obesity. The center collaborates with other UCSD departments as well as external partners. Dr. Patrick is also the co-founder of a company that licenses technologies developed at the center to deliver health programs and services. The document argues that new technologies now enable more integrated, systems-level approaches to health that consider multiple ecological factors simultaneously.
The document discusses applying technology to address healthcare challenges in developing countries. It proposes three models: 1) Using telemedicine to expand access to cardiovascular specialists in Jamaica, reducing wait times for tests and consultations. 2) Launching a 24/7 medical hotline in Nigeria to improve access to doctors, medical information, and clinics. 3) Establishing an emergency medical services system in Enugu, Nigeria led by medical professionals with equipped vehicles to respond to emergencies. The models aim to improve healthcare access, quality and reduce costs through innovative use of technology.
The Medicines Patent Pool Presentation during the session "Market Interventions for Innovation and Access", UN High Level Meeting on HIV/AIDS
New York, 9 June 2011
The document summarizes the components and goals of the Affordable Care Act and National Prevention Strategy, and discusses how community prevention programs can help improve health outcomes and lower healthcare costs. It then describes the role of the Massachusetts Healthy Communities System in supporting community prevention efforts across the state to achieve the goals of increased access to care, prevention services, and policy changes that promote public health.
Real-World Data – What’s Next? by Michael Seewald, AstraZeneca for mHealth Is...Levi Shapiro
Presentation by Michael Seewald, Michael Seewald, Ph.D.
Global Head Evidence, AstraZeneca Biopharmaceuticals for mHealth Israel, October 19th, 2021.
Real-World Data is able to uncover local unmet medical need – Call to action to build Learning Healthcare Systems. Significant Variations in Care and Large Potential for Improvement. Real-World Data helps to benchmark efficient use of resources and detect “waste”. Healthcare systems need to address the problem of waste. But fundamental change is hard, and progress slow. Outcomes Transparency Improves ComplianceExample: Swedish myocardial infarction registry. Outcomes Transparency Improves Compliance. Example: Swedish myocardial infarction registry. Improving Outcomes and Creating Value will continue to guide Learning Healthcare Systems- enabled by RWD. Four technological trends as accelerators on our path. Empowered patients- Molecular screening and 24/7 monitoring driving a step change in diagnosis. Algorithmic decision-making: Artificial intelligence supports physician intelligence. Evidence-generating healthcare systemsLive insights on clinical efficacy from digital monitoring. 360° care delivery. Home replaces hospital via digital therapeutics and on-demand remote support. AstraZeneca Areas of Partnering Interest: (https://www.astrazeneca.com/partnering/our-areas-of-partnering-interest.html).
The document summarizes findings from a report that tracked global development assistance for health from 1990 to 2007. It found that development assistance for health nearly quadrupled over this period, fueled primarily by increases in funding for HIV/AIDS. New actors like the Global Fund and GAVI accounted for an increasing share of assistance. While disease burden and income levels influenced funding allocations, political and economic factors also appeared to play a role in determining which countries received assistance. The report aims to continue annually tracking development assistance to better inform global health policies and priorities.
This document discusses prevention of diabetes-related visual impairment and blindness. It notes that diabetes contributes to many eye diseases that can lead to vision loss or blindness, including cataract, glaucoma, and diabetic retinopathy (DR). DR is responsible for about 1% of global vision impairment and blindness. The document provides global and regional statistics on the prevalence of DR and projections for how these numbers will increase in the future given the rising rates of diabetes worldwide. It also discusses the economic burden of DR and strategies for prevention and management of DR through control and surveillance programs integrated into overall non-communicable disease control efforts.
World Kidney Day was established to raise awareness of chronic kidney disease (CKD) and encourage detection and prevention programs. CKD affects over 20 million Americans and is a major cause of death worldwide. While kidney failure requiring dialysis has increased, CKD is often preventable or treatable through control of diabetes, hypertension, and obesity. World Kidney Day aims to educate the public and healthcare professionals about CKD risks and signs through collaborative events around the world each March.
Health Financing System of United KingdomAditya Sood
Discussing in brief bout the latest statistics of Health Financing in UK, with emphasis on National Health Services (NHS) model and the key challenges being faced by the UK health system financing.
The document discusses declining U.S. competitiveness in biomedical research compared to other countries. It notes that U.S. global leadership in this area grew from scientific research in WWII but that federal funding for biomedical research has not kept pace with inflation. As a result, other countries like China are increasing their funding and output of biomedical research, threatening U.S. leadership. The document recommends that Congress increase and sustain funding for agencies like NIH to at least 0.25% of GDP and support additional policies to maintain U.S. competitiveness in this important industry.
DECLARATION OF HELSINKI - History and principlesanaghabharat01
This SlideShare presentation provides a comprehensive overview of the Declaration of Helsinki, a foundational document outlining ethical guidelines for conducting medical research involving human subjects.
The Power of Vaccines: ‘getting to zero’ for HIV and TB was an event hosted by the TB/HIV and Prevention Working Groups of the UK Consortium on AIDS and International Development. The meeting was sponsored by Pamela Nash MP and held on Friday, 18th May 2012, in Portcullis House, Westminster. Read more at http://storify.com/PamojaUK/the-power-of-vaccines
http://www.pamoja.uk.com
This document discusses the past, present and future of global health engagement by academic institutions. It provides a brief history of global health, from tropical medicine to international health to global health. It discusses definitions of global health and international health. It also outlines the growing interest in global health engagement, including changing US demographics, educational benefits for students, and a commitment to social justice. Key players in global health like the WHO, World Bank, and Gates Foundation are also summarized.
This document discusses lessons that can be learned from international healthcare systems to develop a sustainable healthcare system. It provides 3 key lessons:
1. Prioritize health in policymaking by demonstrating how health impacts productivity, education, employment and economic growth.
2. Increase investment in healthcare through dedicated funding and by legislating specific access entitlements.
3. Engage patients by making services patient-centered, ensuring quality communication of information, and driving continuous quality improvement.
1. Medical technology provides substantial benefits to patients' quality of life, disability levels, and mortality rates compared to traditional treatments like drugs alone.
2. While medical technology increases direct health care costs, it also provides significant economic and productivity benefits to society by reducing time lost from work and increasing overall welfare.
3. Studies show that many medical technologies reduce overall lifetime health care costs and societal costs compared to traditional treatments due to better health outcomes and shorter hospital stays.
Dr. Michael S. Perry - Afternoon Keynote Presentationmarsinnovation
Michael Perry gave a presentation at the MaRS Innovation Summit in Toronto, Canada on October 28, 2010. He discussed trends in pharmaceutical R&D including rising costs of drug development and declining productivity. He noted significant unmet medical needs in areas like oncology, cardiovascular disease, and diabetes. Perry also talked about how venture capital like Bay City Capital is fueling innovation by translating academic research into potential drugs and funding their development through commercialization. However, industry faces challenges like large patent cliffs and risk aversion. Perry proposed strategies like the Pharma Innovation Fund to help bridge gaps in translating discoveries into treatments.
This document discusses the role of evidence and global partnerships in addressing major global health issues and achieving the UN Millennium Development Goals. It outlines how organizations like the World Health Organization, World Bank, and Lancet work together through initiatives like Countdown 2015 and strategic partnerships to generate scientific evidence, advocate for policies, and monitor programs aimed at reducing child and maternal mortality globally. The document also previews upcoming reports from the Lancet on various global health topics like mental health, HIV prevention, and non-communicable diseases.
This document summarizes the work of Dr. Kevin Patrick and the Center for Wireless and Population Health Systems at UC San Diego. The center conducts research using wireless technologies to measure health behaviors and exposures in various populations. This includes projects funded by NIH on personal activity and location tracking, comparative effectiveness research, and text message interventions for obesity. The center collaborates with other UCSD departments as well as external partners. Dr. Patrick is also the co-founder of a company that licenses technologies developed at the center to deliver health programs and services. The document argues that new technologies now enable more integrated, systems-level approaches to health that consider multiple ecological factors simultaneously.
The document discusses applying technology to address healthcare challenges in developing countries. It proposes three models: 1) Using telemedicine to expand access to cardiovascular specialists in Jamaica, reducing wait times for tests and consultations. 2) Launching a 24/7 medical hotline in Nigeria to improve access to doctors, medical information, and clinics. 3) Establishing an emergency medical services system in Enugu, Nigeria led by medical professionals with equipped vehicles to respond to emergencies. The models aim to improve healthcare access, quality and reduce costs through innovative use of technology.
The Medicines Patent Pool Presentation during the session "Market Interventions for Innovation and Access", UN High Level Meeting on HIV/AIDS
New York, 9 June 2011
The document summarizes the components and goals of the Affordable Care Act and National Prevention Strategy, and discusses how community prevention programs can help improve health outcomes and lower healthcare costs. It then describes the role of the Massachusetts Healthy Communities System in supporting community prevention efforts across the state to achieve the goals of increased access to care, prevention services, and policy changes that promote public health.
Real-World Data – What’s Next? by Michael Seewald, AstraZeneca for mHealth Is...Levi Shapiro
Presentation by Michael Seewald, Michael Seewald, Ph.D.
Global Head Evidence, AstraZeneca Biopharmaceuticals for mHealth Israel, October 19th, 2021.
Real-World Data is able to uncover local unmet medical need – Call to action to build Learning Healthcare Systems. Significant Variations in Care and Large Potential for Improvement. Real-World Data helps to benchmark efficient use of resources and detect “waste”. Healthcare systems need to address the problem of waste. But fundamental change is hard, and progress slow. Outcomes Transparency Improves ComplianceExample: Swedish myocardial infarction registry. Outcomes Transparency Improves Compliance. Example: Swedish myocardial infarction registry. Improving Outcomes and Creating Value will continue to guide Learning Healthcare Systems- enabled by RWD. Four technological trends as accelerators on our path. Empowered patients- Molecular screening and 24/7 monitoring driving a step change in diagnosis. Algorithmic decision-making: Artificial intelligence supports physician intelligence. Evidence-generating healthcare systemsLive insights on clinical efficacy from digital monitoring. 360° care delivery. Home replaces hospital via digital therapeutics and on-demand remote support. AstraZeneca Areas of Partnering Interest: (https://www.astrazeneca.com/partnering/our-areas-of-partnering-interest.html).
The document summarizes findings from a report that tracked global development assistance for health from 1990 to 2007. It found that development assistance for health nearly quadrupled over this period, fueled primarily by increases in funding for HIV/AIDS. New actors like the Global Fund and GAVI accounted for an increasing share of assistance. While disease burden and income levels influenced funding allocations, political and economic factors also appeared to play a role in determining which countries received assistance. The report aims to continue annually tracking development assistance to better inform global health policies and priorities.
This document discusses prevention of diabetes-related visual impairment and blindness. It notes that diabetes contributes to many eye diseases that can lead to vision loss or blindness, including cataract, glaucoma, and diabetic retinopathy (DR). DR is responsible for about 1% of global vision impairment and blindness. The document provides global and regional statistics on the prevalence of DR and projections for how these numbers will increase in the future given the rising rates of diabetes worldwide. It also discusses the economic burden of DR and strategies for prevention and management of DR through control and surveillance programs integrated into overall non-communicable disease control efforts.
World Kidney Day was established to raise awareness of chronic kidney disease (CKD) and encourage detection and prevention programs. CKD affects over 20 million Americans and is a major cause of death worldwide. While kidney failure requiring dialysis has increased, CKD is often preventable or treatable through control of diabetes, hypertension, and obesity. World Kidney Day aims to educate the public and healthcare professionals about CKD risks and signs through collaborative events around the world each March.
Health Financing System of United KingdomAditya Sood
Discussing in brief bout the latest statistics of Health Financing in UK, with emphasis on National Health Services (NHS) model and the key challenges being faced by the UK health system financing.
The document discusses declining U.S. competitiveness in biomedical research compared to other countries. It notes that U.S. global leadership in this area grew from scientific research in WWII but that federal funding for biomedical research has not kept pace with inflation. As a result, other countries like China are increasing their funding and output of biomedical research, threatening U.S. leadership. The document recommends that Congress increase and sustain funding for agencies like NIH to at least 0.25% of GDP and support additional policies to maintain U.S. competitiveness in this important industry.
DECLARATION OF HELSINKI - History and principlesanaghabharat01
This SlideShare presentation provides a comprehensive overview of the Declaration of Helsinki, a foundational document outlining ethical guidelines for conducting medical research involving human subjects.
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
Travel Clinic Cardiff: Health Advice for International TravelersNX Healthcare
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
1. Politics and Polypills: Strategies for
Improving Global Cardiovascular Health
Mark Huffman, MD, MPH
Northwestern University Feinberg School of Medicine
16 November 2012
1
4. Are NCDs neglected?
Fuster V, Voute J. Lancet 2005; 366:1512
Horton R. Lancet 2005; 366:1514
5. “Calls to action” published
in medical journals: 1966–2007
Ebrahim S. Int. J. Epidemiol. 2008;37:225-230
6. Potential reasons why NCDs
might be neglected
1. Apathy
NCDs are difficult/complex to tackle
Aren’t NCDs part of normal aging?
Myth that risk factors only account for 50% of deaths
2. Inadequate funding
Development aid for health (DAH) has risen from
$5.6B (1990) to $22B (2007), but how much for NCDs?
3. NCDs are invisible
“Scandal of ignorance” as described by Setel et al.
(lack of vital registration systems)
Stuckler D, et al. in Sick Societies. Eds. Stuckler and Siegel. Oxford, 2011.
7. Who’s “in charge” of NCDs?
World Health Organization
United Nations development agencies
International financial institutions (World Bank, IMF)
National development agencies
Ministries of health
Academic institutions
Private donors (for-profit and not-for-profit groups)
Stuckler D, et al. in Sick Societies. Eds. Stuckler and Siegel. Oxford, 2011.
8. Who’s “in charge” of NCDs?
World Health Organization
United Nations development agencies
International financial institutions (World Bank, IMF)
National development agencies
Ministries of health
Academic institutions
Private donors (for-profit and not-for-profit groups)
3 indicators to assess the power/influence of these institutions:
1) Where does the money come from? How much? Where does it go?
2) Who sits on the board and whose interests do they serve?
3) Who wins conflicts?
Stuckler D, et al. in Sick Societies. Eds. Stuckler and Siegel. Oxford, 2011.
9. Where does the money come from?
DAH commitments (2007): $22B
PRIVATE
MONEY
Ravishankar N, et al. Lancet 2009; 363:2113.
10. Where does the money come from?
DAH commitments (2007): $22B
…but only ~2/3 ($15B) can be accounted for
(and do not represent disbursements)
Ravishankar N, et al. Lancet 2009; 363:2113.
11. But little funding for NCDs ($ millions)
25000
20000
Chronic diseases
15000
Infectious diseases
10000 (HIV, TB, malaria)
Total health aid
5000
0
2001 2002 2003 2004 2005 2006 2007
11
Nugent R, Feigl A. Center for Global Development WP 228, 2011.
12. But little funding for NCDs ($ millions)
25000
20000
Chronic diseases
15000
Infectious diseases
10000 (HIV, TB, malaria)
Total health aid
5000
0
2001 2002 2003 2004 2005 2006 2007NCDs: $0.78/DALY
ID: $23.9/DALY
Total: $16.4/DALY
12
Nugent R, Feigl A. Center for Global Development WP 228, 2011.
13. Who are the NCD funders?
Funder Purpose 5 year total (2004-2008)
WHO (incl. PAHO) General NCDs $873M
Wellcome Trust General NCDs $458M
Bloomberg + Gates Tobacco, cervical cancer $250M
World Bank General NCDs $183M
Novo Nordisk Diabetes $58M
GE Foundation General NCDs $41M
NIH Tobacco, cancer, CVD $27M
InterAmerican Development Bank General NCDs $21M
International Diabetes Federation Diabetes $18M
Hilton Foundation Sense organ diseases $12M
Nugent R, Feigl A. Center for Global Development WP 228, 2011.
14. Who are the NCD funders?
Funder Purpose 5 year total (2004-2008)
WHO (incl. PAHO) General NCDs $873M
Wellcome Trust General NCDs $458M
Bloomberg + Gates Tobacco, cervical cancer $250M
World Bank General NCDs $183M
Novo Nordisk Diabetes $58M
GE Foundation General NCDs $41M
NIH Tobacco, cancer, CVD $27M
InterAmerican Development Bank General NCDs $21M
International Diabetes Federation Diabetes $18M
Hilton Foundation Sense organ diseases $12M
Nugent R, Feigl A. Center for Global Development WP 228, 2011.
15. Who are the NCD funders?
Funder Purpose 5 year total (2004-2008)
WHO (incl. PAHO) General NCDs $873M
Wellcome Trust General NCDs $458M
Bloomberg + Gates Tobacco, cervical cancer $250M
World Bank General NCDs $183M
Novo Nordisk Diabetes $58M
GE Foundation General NCDs $41M
NIH Tobacco, cancer, CVD $27M
InterAmerican Development Bank General NCDs $21M
International Diabetes Federation Diabetes $18M
Hilton Foundation Sense organ diseases $12M
Whose interests are being served? What ties to these organizations have to
food/beverage, agriculture, and pharmaceutical industries?
Nugent R, Feigl A. Center for Global Development WP 228, 2011.
19. WHO Budget, 2000-2013 projected
2007: ~12% of WHO budget directed to NCDs
Nugent R, Feigl A. Center for Global Development WP 228, 2011.
20. Where does the WHO get its money?
Nugent R, Feigl A. Center for Global Development WP 228, 2011.
21. Where does the WHO get its money?
Gates annual operating budget: $3.8B
Gates WHO contribution: $150M (14% of VC)
Nugent R, Feigl A. Center for Global Development WP 228, 2011.
22. Public/global health and politics
Research!America respondents GBD
Siegel KR, et al. Global Health Action 2011; 4:6339.
23. Public/global health and politics
5 types of political incentives:
1. Political: squeaky wheel
2. Economic: private companies seek to shift priorities
3. Organizational: sustaining (or growing) the status quo
4. Symbolic: MDGs
5. Scientific: technical arguments (weakest)
Political economy of NCDs will likely remain weak without
paying attention to these incentives
Stuckler D, et al. in Sick Societies. Eds. Stuckler and Siegel. Oxford, 2011.
30. WHO Indicators/Targets Meeting:
Nov 5-7, 2012
119 Member States; 9 Voluntary Targets by 2025
25% reduction in mortality from CVD, cancer, DM, and chronic lung disease
10% reduction in harmful use of alcohol
10% reduction in insufficient physical activity
Halt the rise in diabetes and obesity
25% reduction in prevalence of raised blood pressure
30% reduction mean population sodium intake (<20000 mg sodium)
30% reduction in tobacco use
50% of eligible people receive drugs/counseling to prevent heart attacks, strokes
80% availability of affordable basic technologies and essential medicines, including
generics, required to treat major NCDs in both public and private facilitates
30
who.int
31. Questions about “25 by 25”
Buy-In
• Only 19 member states provided comments after posted to web, followed
by 22 member states when requested via email/web survey (?overlap) to
the initial set of targets, suggesting low buy-in.
Mechanisms for Monitoring
• Monitoring risk factors q5 years via WHO Steps
• Monitoring of policies: ?systematic review ; ?funding
• Reporting q5 year at the WHA and UN GA
Methodologic Factors
• Baseline mortality rates: unavailable for ~40% of WHO Member States
• Reference population standard has not been defined
(can influence comparisons)
• Younger countries with more premature deaths have more tougher climb
31
who.int
32. All “25 by 25” Targets Are Not Created Equal
NCD deaths under 70 25% reduction in
as % of all NCD deaths premature NCD deaths
(2008) (2025)
Country Male Female Male Female
Afghanistan 81 72.2 60.8 54.2
Brazil 52.3 42.2 39.2 31.7
China 43.9 32 32.9 24.0
India 61.8 55 46.4 41.3
Russian Federation 55 25.4 41.3 19.1
South Africa 69 53.7 51.8 40.3
United States of America 36.5 23.6 27.4 17.7
32
who.int
36. Possibilities
80% reduction in CVD events (predicted)
Increased adherence
Less reliance on physicians
Lower cost
Problems
Primary vs. secondary prevention
Emphasis on pills > lifestyle > policies
Dose titration, side effects
Lower margins
37. Polypill®, or Fixed Dose Combination, Origins
Goals:
• 4 drugs in 1
(ASA, BB, ACE, statin)
• Improve adherence
• Lower cost
Richard Peto
38. Research Requirements for Polypill®
1) Stability testing
2) Bioavailability testing
3) Assessment of short-term effects on BP, LDL cholesterol,
and platelet aggregation
4) Assessment of safety and short-term symptomatic side
effects
5) Study of interactions and effects on combination of drugs
on physiologic mechanisms
6) Studies on adherence to treatment
Multiple polypills (at least 2 doses per drug) envisioned
WHO/Wellcome Trust were charged with partnering with
industry for testing, including cost-effectiveness via RCTs or
community demonstration projects (5-year timeline!)
39. Was 80% Risk
Reduction Realistic?
Reduction IHD event risk Stroke risk
Risk factor Agent in risk factor reduction (%) reduction (%)
LDL cholesterol Statin 70 mg/dl 61 (51 to 71) 17 (9 to 25)
3 classes of drug at 11 mmHg
Blood pressure 46 (39 to 53) 63 (55 to 70)
half standard dose (DBP)
Serum
Folic acid (0.8 mg/d) 3 μmol/L 16 (11 to 20) 24 (15 to 33)
homocysteine
Not
Platelet function Aspirin (75 mg/d) 32 (23 to 40) 16 (7 to 25)
quantified
Combined effect All 88 (84 to 90) 80 (71 to 87)
Wald and Law. BMJ, 2003.
41. The Indian Polycap Study (TIPS)
2,053 patients with 1 major risk factor included; 12 week trial in India (2007-2008)
Polycap: ASA 100 mg, simvastatin 20 mg, atenolol 50 mg, ramipril 5 mg, HCTZ 12.5 mg
Manufactured by Cadila Pharmaceuticals, Ltd.
Yusuf S, et al. Lancet, 2009;373:1341.
42. Polycap’s Short-Term Effects
Blood pressure= 5.7 mmHg fall Platelet aggregation
LDL = 31 mg/dl fall
Projected Risk Reduction
IHD Stroke
Wald/Law 88% 80%
Polycap 62% 48%
Yusuf S, et al. Lancet, 2009;373:1341.
44. Low Secondary Prevention Rx Rate: PURE
CHD Stroke
153,996 participants across 628 urban/rural communities in 17 countries (2003-
2009)
Yusuf S, et al. Lancet, 2011; 378:1231.
46. (Potential) Limitations of Polypill
“How will I be able to evaluate my patients’ side effects
of the individual medications?”
• Possibly overstated given distinctions across drugs
-Bleeding vs. mylagias vs. orthostasis vs. cough
“I need to titrate the doses of my patients’ drugs.”
• Limited role dose escalation/de-escalation for most patients
-Low dose aspirin and high-dose statin preferred for 2o prev.
• Likely does not require cardiologist, nor even physician
“What about clopidogrel for my post-MI patients?”
47. Estimated Costs
of 5 Priority Interventions
Cost per person
Interventions per year
China India Russia
Tobacco FCTC 0.14 0.16 0.49
Mass-media, voluntary action
Dietary salt 0.05 0.06 0.16
by food industry
Mass-media, food taxes,
Obesity, unhealthy diet
subsidies, labeling and 0.43 0.35 1.18
and physical inactivity
marketing restriction
Tax, advertising bans,
Harmful alcohol intake 0.07 0.05 0.52
restricted access
Cardiovascular risk Combination of drugs,
1.02 0.9 1.73
reduction polypharmacy
Total cost per person 1.72 1.52 4.08
Beaglehole R, et al. Lancet 2011; 377:1438.
48. Cost-effectiveness of Polypill
for CVD in India (per 1M/10yrs)
> 35% > 25% > 15%
Costs and Effects No Polypill Risk Risk Risk
Total cost (millions) $23.5 $34.5 $51.4 $92.2
MI averted -- 10,200 14,400 21,300
Deaths from CHD
averted -- 10,500 13,500 19,600
Cost per DALY
averted
-- $300 $990 $1,500
Note: Each strategy is compared with no polypill.
Disease Control Priorities in Developing Countries, 2nd edition, 2006, Table 45.6
49. Polypill 2o Prevention Trials
Sample Primary
Title Manufacturer Sponsor Size Outcome
UMPIRE Dr. Reddy’s Lab European Comm. 2,000 Adherence
IMPACT Dr. Reddy’s Lab Health Research 600 Adherence
Council (NZ)
Kayini GAP Dr. Reddy’s Lab National Health and 1,000 Adherence
Research Council
(Australia)
SPACE Dr. Reddy’s Lab Hospital do 2,000 Adherence
Coracao
FOCUS* Ferrer CINI/Ferrer 4,000 Adherence
TIPS-K* Cadila Cadila 500 Adherence
*Only two “true” 2o prevention trials; others include high CV risk (>15% over 5 years)
49
Prabhakaran D, et al. Clin Invest 2012; in press.
50. UMPIRE 1o Results
Fixed-dose
combination Usual care Treatment effect
Outcome (n=1002) (n=1002) (95% CI)
1.33
Adherence (%) 86 65
(1.26 to 1.41)
Systolic blood -2.6
129.2 131.7
pressure (mm Hg) (-4.0 to -1.1)
LDL cholesterol, -0.11
2.18 (84.3) 2.29 (88.5)
mmol/L (mg/dL) (-0.17 to -0.05)
"If we could address the shortfall in adherence, we would
do more [for CVD prevention] than generating another
blockbuster drug for a single risk factor.”
-Simon Thom, November 6, 2012
50
theheart.org
51. September December January March April
8-month timeline of events
51
57. In-hospital Event Rates
(p<0.01 for all)
12
Total
10 STEMI
8 Non-STEMI
Unstable Angina
%6
4
2
0
Death (%) Reinfarction (%) Stroke (%) ardiogenic shock (%)
Death, reinfarction, stroke, heart failure, or
C
57
Mohanan P, et al. Eur Heart J 2012; Sept 7 [Epub ahead of print]
58. Evaluation of Patient Characteristics
and In-Hospital Outcomes
In-hospital death In-hospital MACE
OR (95% CI) OR (95% CI)
Adjusted for age, sex, socioeconomic position (education), modified GRACE risk score
variables**, and within-hospital clustering (random effects model)
2.65 2.24
STEMI vs. unstable angina (ref)
(1.49, 4.69) (1.43, 3.52)
0.94 1.10
NSTEMI vs. unstable angina (ref)
(0.50, 1.78) (0.67, 1.81)
2.31 1.94
Symptom to door >6 hrs vs. <6 hrs (ref)
(1.75, 3.05) (1.55, 2.44)
1.81 1.75
Door-to-needle >30 min vs. <30min (ref)
(1.38, 2.38) (1.38, 2.21)
1.78 2.69
Inappropriate thrombolysis*
(1.08, 29.2) (1.88, 3.87)
*Non-STEMI and unstable angina only
**GRACE risk score variables include: age, heart rate, systolic blood pressure, serum creatinine, Killip class,
58
cardiac enzyme, and ST segment deviation. Cardiac arrest at presentation excluded (not available).
59. NEWS FLASH!
Optimal Care is Better than Non-Optimal Care
Non optimal in- Optimal in-
hospital hospital
medical therapy medical Adjusted OR*
(ref) therapy (95%CI)
*Adjusted for modified GRACE risk score variables: age, HR, SBP, SCr, Killip class, cardiac enzyme, and ST
segment deviation and within-hospital clustering. Cardiac arrest at presentation excluded (N/A).
N (%) N=15,411 (60) N=10,307 (40)
0.93
Death 632 (4.1) 366 (3.6)
(0.71, 1.22)
Death, reinfarction, 0.79
938 (6.1) 532 (5.2)
stroke, HF, or shock (0.63, 0.99)
Prabhakaran D, et al. AHA 2012 Scientific Sessions.
60. Optimal in-hospital Optimal discharge
medical therapy medical therapy
OR (95% CI) OR (95% CI)
Adjusted for modified GRACE risk score variables: age, HR, SBP, SCr, Killip class, cardiac enzyme (positive vs. negative), and ST
segment deviation and within-hospital clustering. Cardiac arrest at presentation excluded (N/A).
1.00 1.00
Age
(1.00, 1.01 (0.99, 1.00)
1.00 1.00
Women vs. men (ref)
(0.90, 1.12) (0.89, 1.13)
1.01 1.00
Heart rate (per bpm)
(1.00, 1.01) (1.00, 1.00)
1.00 1.00
Systolic blood pressure (per mmHg)
(1.00, 1.00) (1.00, 1.00)
0.56 0.67
Killip >1 vs. 1 (ref)
(0.50, 0.63) (0.59, 0.75)
1.17 1.71
NSTEMI vs. unstable angina (ref)
(0.95, 1.45) (1.35, 2.16)
0.51 1.39
STEMI vs. unstable angina (ref)
(0.42, 0.62) (1.15, 1.68)
2.14 0.74
Enzyme positive vs. negative (ref)
(1.75, 2.62) (0.60, 0.90)
1.03 0.97
Creatinine (per mg/dl)
(0.97, 1.10) (0.90, 1.04)
Optimal in-hospital medical therapy vs. 10.48
60 --
non optimal (ref) (9.37, 11.72)
61. ACS Quality Improvement in Kerala
(ACS QUIK): 2012-2017
• Cluster-randomized, stepped wedge clinical trial
• Aim to develop, implement, and evaluate quality
improvement toolkit on 30 day MACE (9.3%7.3%)
• Focus group discussions (Nov 2012) with help from Drs.
David Victorson and Shifalika Goenka to build toolkits
• Audit/feedback, standardized clinical pathways,
checklists (likely including Polycap or other avail. FDC)
• 2o outcomes: process of care, hrQOL, microeconomic
impact
61
62. Take Home Points
Politics
Evidence is necessary but insufficient for political change;
private forces dominate NCD landscape of weak political econ.
WHO 25 by 25
“Premature” focus on individuals <70 years; questions on buy-
in, monitoring, and methodology
Polypills®
More difficult/expensive than anticipated; 33% increased
adherence; 50-60% risk reduction; not just for LMICs
ACS QUIK
Hospital-based QI may be future source of frugal innovations
63. Politics and Polypills®: Strategies for
Improving Global Cardiovascular Health
Mark Huffman, MD, MPH
Northwestern University Feinberg School of Medicine
16 November 2012
63